Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3

N Natasha B. Leighl N Nofisat Ismaila (American Society of Clinical Oncology (ASCO), Alexandria, VA, US) G Greg Durm (Indiana University Health, Indianapolis, IN, US) N Narjust Florez (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) J Janet Freeman-Daily (The ROS1ders, Seattle, WA) B Bruna Pellini D Deebya Raj Mishra (BP Koirala Institute of Health Sciences, Dharan, Nepal) E Erin L. Schenk (University of Colorado Anschutz Medical Center, Aurora, CO) L Lecia Sequist (Massachusetts General Hospital, Boston, MA) N Navneet Singh (Department of Chemistry, Indian Institute of Technology Delhi 1 , Hauz Khas, New Delhi 110016,) L Lyudmila Bazhenova (University of California, San Diego, San Diego, CA, US)

Abstract

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline .

Article Details

Volume / Issue Vol. 43, Issue 10
Published April 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

N

Natasha B. Leighl

N

Nofisat Ismaila

American Society of Clinical Oncology (ASCO), Alexandria, VA, US

G

Greg Durm

Indiana University Health, Indianapolis, IN, US

N

Narjust Florez

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

J

Janet Freeman-Daily

The ROS1ders, Seattle, WA

B

Bruna Pellini

D

Deebya Raj Mishra

BP Koirala Institute of Health Sciences, Dharan, Nepal

E

Erin L. Schenk

University of Colorado Anschutz Medical Center, Aurora, CO

L

Lecia Sequist

Massachusetts General Hospital, Boston, MA

N

Navneet Singh

Department of Chemistry, Indian Institute of Technology Delhi 1 , Hauz Khas, New Delhi 110016,

L

Lyudmila Bazhenova

University of California, San Diego, San Diego, CA, US